Quick Answer
ADIAL PHARMACEUTICALS, INC. reported R&D Expense of $2.62 million for fiscal year 2025.
ADIAL PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.62M | -18.9% |
| 2024 | $3.23M | +154.9% |
| 2023 | $1.27M | -35.0% |
| 2022 | $1.95M | -76.8% |
| 2021 | $8.40M | +43.4% |
| 2020 | $5.85M | +47.6% |
| 2019 | $3.97M | +976.3% |
| 2018 | $368.5K | +102.3% |
| 2017 | $182.1K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $521.1K | -49.5% | -28.8% |
| June 30, 2025 | $732.3K | -27.7% | -2.0% |
| March 31, 2025 | $746.9K | +64.4% | -27.6% |
| September 30, 2024 | $1.03M | +398.1% | +1.9% |
| June 30, 2024 | $1.01M | +135.5% | +122.9% |
| March 31, 2024 | $454.3K | +24.3% | +119.3% |
| September 30, 2023 | $207.1K | -70.2% | -51.8% |
| June 30, 2023 | $429.9K | -36.8% | +17.6% |
- ADIAL PHARMACEUTICALS, INC. showed a decrease of -18.9% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, ADIAL PHARMACEUTICALS, INC.’s r&d expense has grown by 1338.5% (from $182.1 thousand to $2.62 million).
- The most recent figure is from ADIAL PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: